<DOC>
	<DOCNO>NCT00125359</DOCNO>
	<brief_summary>The purpose study learn effect two new anticancer drug , erlotinib ( Tarceva ) bexarotene ( Targretin ) , treat patient advanced lung cancer . Erlotinib approve Food Drug Administration ( FDA ) treatment non-small-cell lung cancer ( NSCLC ) . Bexarotene approve FDA treatment cutaneous T-cell lymphoma . This combination drug experimental .</brief_summary>
	<brief_title>Study Tarceva Targretin Oral Capsules Patients With Advanced Lung Cancer</brief_title>
	<detailed_description>This single institution open label phase II trial . Consecutive , eligible patient present diagnosis advance NSCLC enrol study . All eligible patient receive continuous daily oral erlotinib 150 mg ( Tarceva™ ) daily bexarotene oral capsule 400 mg/m2 ( Targretin® ) . The two agent take time . We anticipate maximum accrual 40 patient trial . Patients evaluated history , physical examination , laboratory assessment every 4 week . Radiographic disease assessment chest radiograph obtain every 4 week computer tomography every 8 week longer clinically indicate . Whole body PET scan obtain 10 day 8 week . All radiographic study send Medical Metrix Solutions ( MMS ) independent radiographic review tumor response .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NSCLC Prior chemotherapy radiotherapy allow . Hepatic renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>tarceva</keyword>
	<keyword>targretin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Carcinoma , non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>